Life Sciences Tools and Services

Sun-Novo

Sun-Novo released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 197.1 M, actual EPS CNY 0.18

Sun-Novo to release FY2025 earnings on April 27 During-Market BJT, forecast revenue CNY 1.281 B, EPS CNY 2.05

Sun-Novo FY2026 Q1 Earnings Release on April 24 After-Market BJT

Sun-Novo released FY2025 earnings on February 27 During-Market (BJT), actual revenue CNY 1.222 B (forecast CNY 1.281 B), actual EPS CNY 1.861 (forecast CNY 2.05)

Sun-Novo released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 366.49 M, actual EPS CNY 0.3709

Sun-Novo released FY2025 Q3 earnings on October 29 Pre-Market (BJT), actual revenue CNY 265.46 M, actual EPS CNY 0.3077

Sun-Novo released FY2025 9 Months Earnings on October 29 Pre-Market (BJT), actual revenue CNY 855.76 M, actual EPS CNY 1.4849

Sun-Novo to Release FY2025 Q3 Earnings Report on October 30, Pre-Market BJT

Sun-Novo released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), actual revenue CNY 590.3 M, actual EPS CNY 1.18

Sun-Novo released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 359.46 M, actual EPS CNY 0.9072

Sun-Novo to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Huansan Securities Gives Buy Rating to Yangguang Nuohé

Tan Guochao of Huaxan Securities Gives Sunlight Nuhe a Buy Rating

SunnyNuohuo Responds to GLP-1 Drug Technology Reserves and Market Layout

Huachen Securities Upgrades Rating of Sunlight Nuohuo to Buy

Sunshine Nuohuo's Secretary Responds to Strategic Layout

NHKC-1 Modified Innovative Drug Enters Phase III Clinical Trials

Huansan Securities Gives Buy Rating and Future Earnings Forecast for Yangguang Nuohet

Sunshine Novo Discloses Small Nucleic Acid R&D Platform Setup

Sunshine Norah Plans to Acquire Controlling Shareholder Li Qian's Holdings in Langyan Life

688621

Sun-Novo announced that Hang Seng Pharmaceutical needs to pay 2.4032 million yuan to the company due to the first-instance judgment result. In the judgment, Hang Seng Pharmaceutical is required to pay 4.4032 million yuan for research and development expenses and compensation, while Sun-Novo needs to compensate 2 million yuan. The case acceptance fee is borne by Hang Seng Pharmaceutical at 74,500 yuan, and Sun-Novo at 48,000 yuan. The company has fully accrued bad debt provisions, so the lawsuit has no negative impact on profits, and the case is still within the appeal period

Zhitong

Sun-Novo: The first-instance judgment of the lawsuit requires Hang Seng Pharmaceutical to pay 2.4032 million yuan

Sun-Novo announced that the company intends to acquire 100% equity of Jiangsu Langyan Life Science Technology Holdings Co., Ltd. through the issuance of shares and convertible corporate bonds, and to issue shares to no more than 35 specific investors to raise supporting funds. Before this transaction, the controlling shareholder Li Qian and his concerted actors held 28.27% of the company's shares, and after the transaction is completed, the shareholding ratio will exceed 30%. The company's board of directors has submitted a request to the shareholders' meeting to approve Li Qian and his concerted actors' exemption from increasing their shareholding through a tender offer, and the relevant proposal still needs to be reviewed and approved by the shareholders' meeting

Sun-Novo: Plans to acquire Langyan Life and increase its shareholding to over 30%

According to the Zhitong Finance APP, Sun-Novo announced that the company plans to invest RMB 15 million of its own funds to subscribe for an additional registered capital of RMB 110,556 in Yuanma Zhiyao. After the capital increase is completed, it will hold an 8.20% equity stake. This initiative aims to advance the overall strategic layout in the field of in vivo CAR-T cell therapy and nucleic acid drugs

Sun-Novo plans to invest 15 million yuan in JiaoYuanMa ZhiYao

According to the Zhitong Finance APP, Sun-Novo announced that its subsidiary Jiangsu Novo Biotech Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for the company's research project BTP4507 has been approved. BTP4507 is intended for the treatment of patients with primary hypertension who have poor response to monotherapy

Sun-Novo: BTP4507 has received the notification of approval for clinical trials

Pacific Securities released a research report indicating that the pharmaceutical industry is gradually recovering, with the CXO sector achieving operating revenue of 47.096 billion yuan in the first half of 2025, a year-on-year increase of 13.25%, and a net profit attributable to the parent company of 11.743 billion yuan, a year-on-year increase of 61.19%. It is recommended to focus on themes such as clinical CRO, upstream research, and AI/weight loss drugs, with expectations that domestic and overseas demand will continue to recover. Industry demand is stabilizing, orders are slightly rebounding, and overall performance is improving

Pacific Securities: The pharmaceutical industry is stabilizing and improving, with signs of recovery already visible

603127

06127

The concept of CRO has strengthened amid fluctuations. As of the time of writing, Boteng Co., Ltd. has risen over 9%, JOINN has increased by more than 8%, and Sun-Novo, Ruizhi Pharmaceutical, and Kanglonghua Cheng have also followed suit

JOINN

CRO concept fluctuates and strengthens, Boteng Co., Ltd. rises over 9%

688202

603669

301363

The A-share CRO concept sector has seen a surge, with Lionco hitting the daily limit, MeHow rising over 10%, and Haoyuan Pharmaceutical, Boji Pharmaceutical, Medicilon, Sun-Novo, and Heyuan Biotechnology also following suit

Medicilon

Lionco

MeHow

688336

688098

300049

300199

688091

In the morning session, the innovative drug concept became active again, with Shen Lian Biomedical hitting a two-day limit-up, Furui Co., Ltd. reaching a 20% limit-up, and HYBIO, Sun-Novo, SHANGHAI YIZHONG, and Sunshine Guojian Pharmaceutical rising over 5%. According to news, the "China Innovative Drug and Medical Device Multi-Payment White Paper" shows that the estimated scale of China's innovative drug and medical device market in 2024 is about 162 billion yuan. The white paper predicts that by 2035, the market size of innovative drugs and medical devices in China will exceed 1 trillion yuan

Sunshine Guojian Pharmaceutical

Shen Lian Biomedical

Furui Co.,Ltd.

HYBIO

SHANGHAI YIZHONG

The concept of innovative drugs is active again, Shen Lian Biomedical has achieved a two-day limit up

002923

300584

Innovative drug concept stocks experienced a surge, with Rundu Pharma hitting the limit up, Hicin Pharmaceutical and Sun-Novo rising over 10%, and Huaren Health, Fuyuan Pharmaceutical, and Guangshengtang also climbing

Rundu Pharma

Hicin Pharmaceutical

Innovative drug concept stocks show unusual upward movement, Sun-Novo rises over 10%

The medical services sector surged sharply, with Sun-Novo rising over 10%, followed by gains in Hitec Products, Yinuo Si, Chengdu Xian Dao, Nuo He Zhi Yuan, and Hong Bo Pharmaceutical

The medical services sector surged sharply, with Sun-Novo rising over 10%

Sun-Novo(688621.SH)